These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26465080)

  • 1. Quinone reductase 2 as a promising target of melatonin therapeutic actions.
    Boutin JA
    Expert Opin Ther Targets; 2016; 20(3):303-17. PubMed ID: 26465080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate.
    Boutin JA; Marcheteau E; Hennig P; Moulharat N; Berger S; Delagrange P; Bouchet JP; Ferry G
    J Pineal Res; 2008 Nov; 45(4):524-31. PubMed ID: 18826489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.
    Calamini B; Santarsiero BD; Boutin JA; Mesecar AD
    Biochem J; 2008 Jul; 413(1):81-91. PubMed ID: 18254726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new inhibitors of quinone reductase 2.
    Ferry G; Hecht S; Berger S; Moulharat N; Coge F; Guillaumet G; Leclerc V; Yous S; Delagrange P; Boutin JA
    Chem Biol Interact; 2010 Jul; 186(2):103-9. PubMed ID: 20399199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinone reductase 2 and antidepressant effect of melatonin derivatives.
    Oxenkrug GF; Bachurin SO; Prakhie IV; Zefirov NS
    Ann N Y Acad Sci; 2010 Jun; 1199():121-4. PubMed ID: 20633117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones.
    Cassagnes LE; Perio P; Ferry G; Moulharat N; Antoine M; Gayon R; Boutin JA; Nepveu F; Reybier K
    Free Radic Biol Med; 2015 Dec; 89():126-34. PubMed ID: 26386287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of melatonin in the reduction of oxidative stress. A review.
    Reiter RJ; Tan DX; Osuna C; Gitto E
    J Biomed Sci; 2000; 7(6):444-58. PubMed ID: 11060493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin: an ancient molecule that makes oxygen metabolically tolerable.
    Manchester LC; Coto-Montes A; Boga JA; Andersen LP; Zhou Z; Galano A; Vriend J; Tan DX; Reiter RJ
    J Pineal Res; 2015 Nov; 59(4):403-19. PubMed ID: 26272235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Melatonin as an antioxidant].
    Skrzydlewska E
    Postepy Hig Med Dosw; 2001; 55(6):871-89. PubMed ID: 11875783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms.
    Hardeland R; Coto-Montes A; Poeggeler B
    Chronobiol Int; 2003 Nov; 20(6):921-62. PubMed ID: 14680136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis.
    Boutin JA; Saunier C; Guenin SP; Berger S; Moulharat N; Gohier A; Delagrange P; Cogé F; Ferry G
    Arch Biochem Biophys; 2008 Sep; 477(1):12-9. PubMed ID: 18502195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin.
    Skaper SD; Floreani M; Ceccon M; Facci L; Giusti P
    Ann N Y Acad Sci; 1999; 890():107-18. PubMed ID: 10668417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions.
    Zhang HM; Zhang Y
    J Pineal Res; 2014 Sep; 57(2):131-46. PubMed ID: 25060102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
    Mailliet F; Ferry G; Vella F; Berger S; Cogé F; Chomarat P; Mallet C; Guénin SP; Guillaumet G; Viaud-Massuard MC; Yous S; Delagrange P; Boutin JA
    Biochem Pharmacol; 2005 Dec; 71(1-2):74-88. PubMed ID: 16293234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin and Oxidative Stress in the Diabetic State: Clinical Implications and Potential Therapeutic Applications.
    Espino J; Rodríguez AB; Pariente JA
    Curr Med Chem; 2019; 26(22):4178-4190. PubMed ID: 29637854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the redox cycle of human quinone reductase 2.
    Reybier K; Perio P; Ferry G; Bouajila J; Delagrange P; Boutin JA; Nepveu F
    Free Radic Res; 2011 Oct; 45(10):1184-95. PubMed ID: 21762045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin: action as antioxidant and potential applications in human disease and aging.
    Bonnefont-Rousselot D; Collin F
    Toxicology; 2010 Nov; 278(1):55-67. PubMed ID: 20417677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of melatonin ligands.
    Delagrange P; Boutin JA
    Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance.
    Hardeland R
    Endocrine; 2005 Jul; 27(2):119-30. PubMed ID: 16217125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin and its atheroprotective effects: a review.
    Favero G; Rodella LF; Reiter RJ; Rezzani R
    Mol Cell Endocrinol; 2014 Feb; 382(2):926-37. PubMed ID: 24291636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.